ENG
SITE MAP
About Us
R&D
Contact
Online Contact Us
R&D
- Technology
- R&D Pipeline
- Service
R&D 
Technology
SYSBIOGEN
Technology
Development of machine learning-based cancer diagnosis technology
-
STEP. 1 Primer design
Primer design
for target genes -
STEP. 2 Sample
Samples obtained
by liquid biopsy
(urine and blood) -
STEP. 3 Real-time
polymerase
chain reactionMultiplex real-time
polymerase chain reaction
for target genes -
STEP. 4 Machine
learning-based
analysisApplication
of personalized medicine
-
STEP. 1 Primer design
Primer design
for target genes -
STEP. 2 Sample
Samples obtained
by liquid biopsy
(urine and blood) -
STEP. 4 Machine
learning-based
analysisApplication
of personalized medicine -
STEP. 3 Real-time
polymerase
chain reactionMultiplex real-time
polymerase chain reaction
for target genes
- SYSBIOGEN is developing molecular diagnostic technology based on machine learning.
- Through this technology, SYSBIOGEN aims to improve sensitivity and specificity compared to existing diagnostic systems.
-
Through this technology, SYSBIOGEN aims to establish an early diagnosis system for prostate cancer.
Registered domestic patent
(No. 10-2550113, ‘BIOMARKER FOR DIAGNOSING PROSTATE CANCER AND USE THEREOF’)
in June 2023Application completed in December 2023 in 5 countries including the US, Japan, and Europe, and patent in progress
- Based on the above, SYSBIOGEN plans to expand into an early diagnosis system for various cancers.
Detection of specific cancers by mutation-specific PCR amplification based on BDA technology
-
Conventional method -
Blocker Displacement Amplification
- Based on BDA (Blocker Displacement Amplification) technology, SYSBIOGEN is developing a technology to detect extremely small amounts of mutant genes derived from cancer cells by applying a technology that amplifies the specific mutation region to qPCR or NGS systems.
- This technology can detect mutations at low concentrations (0.01% VAF) with high sensitivity and specificity.
- This technology can be applied to various fields, such as companion diagnosis and detection of minimal residual disease.